Intrathecal insulin-like growth factor 1 but not insulin enhances myelin repair in young and aged rats. (1st May 2017)

• Record Type: Journal Article
• Authors: Hlavica, Martin; Delparente, Aro; Good, Andrin; Good, Nicolas; Plattner, Patricia S.; Seyedsadr, Maryam S.; Schwab, Martin E.; Figlewicz, Dianne P.; Ineichen, Benjamin V.
• Is Part Of: Neuroscience letters. Volume 648(2017)
• Page Start: 41
• Page End: 46
• Publication Date: 2017-05-01
• Subjects: Multiple sclerosis -- Lysolecithin -- IGF-1 -- Insulin -- Remyelination -- Rat -- Intrathecal; Neurology -- Periodicals; Neurology -- Periodicals; Research -- Periodicals; Neurologie -- Périodiques; Neuroanatomie -- Périodiques; Neuropharmacologie -- Périodiques; Neurophysiologie -- Périodiques; Neurology; Periodicals; Electronic journals; 617.48
• DOI: 10.1016/j.neulet.2017.03.047
• Languages: English
• ISSNs: 0304-3940

Abstract

Highlights: Insulin-like growth factor 1 (IGF-1) enhanced remyelination in young and aged rats. Insulin, functionally related to IGF-1, did not enhance remyelination. Aged rats show less pronounced myelin repair compared to young rats. Aged rats are model for chronic demyelination faced in chronic multiple sclerosis. Abstract: One main pathological hallmark of multiple sclerosis (MS) is demyelination. Novel therapies which enhance myelin repair are urgently needed. Insulin and insulin-like growth factor 1 (IGF-1) have strong functional relationships. Here, we addressed the potential capacity of IGF-1 and insulin to enhance remyelination in an animal demyelination model in vivo . We found that chronic intrathecal infusion of IGF-1 enhanced remyelination after lysolecithin-induced demyelination in the spinal cord of young and aged rats. Aged rats showed a weaker innate remyelination capacity and are therefore a good model for progressive MS which is defined by chronic demyelination. In contrast to IGF-1, Insulin had no effect on remyelination in either age group. Our findings highlight the potential use of IGF-1 as remyelinating therapy for MS, particularly the progressive stage in which chronic demyelination is the hallmark.